期刊文献+

临床护理路径在甲状腺癌术后行^(131)I治疗患者中的应用

Application of clinical nursing path for patients undergoing ^(131)I therapy after thyroidectomy for thyroid carcinoma
下载PDF
导出
摘要 目的探讨临床护理路径在甲状腺癌行^(131)I治疗患者中的应用效果。方法选取2016年1月—12月住院的120例甲状腺癌行^(131)I治疗的患者为研究对象,随机分为干预组和对照组,各60例。对照组实施传统护理模式,干预组实施临床护理路径。观察2组患者对疾病基本知识和放射防护知识的掌握情况,及护理满意度。结果干预组患者对疾病基本知识和放射防护知识的掌握情况均优于对照组(P<0.01)。干预组患者对护理工作的总满意度高于对照组(P<0.05)。结论临床护理路径在甲状腺癌行^(131)I治疗的患者中的应用效果良好,能够提高患者对健康知识的掌握和对护理工作的满意度。 bObjective To investigate the effect of clinical nursing path for patients undergoing131 I therapy after thyroidectomy for thyroid carcinoma. Methods Totally 120 patients undergoing131 I therapy after thyroidectomy for thyroid carcinoma were assigned to the intervention group and the control group. The control group received routine care during treatment,and the clinical nursing path was carried out in the intervention group. The knowledge level on disease and radiological protection and satisfaction degree of patients were evaluated. Results Patients in the intervention group were more aware of disease and radiological protection knowledge compared with those in the control group( P〈0. 01). The overall satisfaction rate was higher in the intervention group than that of controls( P〈0. 05). Conclusion The clinical nursing path has good effect on the management of thyroid carcinoma patients with131 I therapy,which can enhance the awareness of patients on disease and radiological protection.
作者 张晨
出处 《中西医结合护理(中英文)》 2017年第9期133-135,共3页 Journal of Clinical Nursing in Practice
关键词 临床护理路径 甲状腺癌 同位素碘 放射治疗 护理管理 clinical nursing path thyroid carcinoma iodine isotope radiotherapy nursing management
  • 相关文献

参考文献6

二级参考文献89

  • 1Kloos RT, Duvuuri V, Jhiang SM, et al. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab, 2002, 87 : 5817-5820.
  • 2Van Nostrand D, Neutze J, Atkins F. Side effects of "rational dose" ^131I therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med, 1986, 27: 1519-1527.
  • 3Van Nostrand D. The benefits and risks of ^131I therapy in patients with well-differentiated thyroid cancer. Thyroid, 2009, 19 : 1381- 1391.
  • 4Guven A, Salman S, Boztepe H, et al. Parathyroid changes after high dose radioactive iodine in patients with thyroid cancer. Ann Nucl Med, 2009, 23: 437-441.
  • 5Grewal RK, Larson SM, Pentlow CE, et al. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J Nucl Med, 2009, 50: 1605-1610.
  • 6Jentzen W, Hobbs RF, Stahl A, et al. Pre-therapeutie ^124I PET(/CT) dosimetry confirms low average absorbed doses per administered ^131I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging, 2010, 37 : 884-895.
  • 7Liu B, Kuang A, Huang R, et al. Influence of vitamin C on salivary absorbed dose of ^131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial. J Nucl Med, 2010, 51: 618-623.
  • 8Raza H, Khan AU, Hameed A, et al. Quantitative evaluation of salivary gland dysfunction after radioiodine therapy using salivary gland scintigraphy. Nucl Med Commun, 2006, 27: 495-499.
  • 9Ish-Shalom S, Durleshter L, Segal E, et al. Sialochemical and oxidative analyses in radioactive ^131I-treated patients with thyroid carcinoma. Eur J Endocrinol, 2008, 158 : 677-681.
  • 10Rosario PW, Borges MA, Purisch S. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with ^131I is associated with lowered radiotoxicity. J Nucl Med, 2008, 49 : 1776-1782.

共引文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部